Health Care [ 3/12 ] | Pharmaceuticals [ 37/74 ]
NASDAQ | Common Stock
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases.
Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.
The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology.
Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 23 | -1.31 Increased by +63.61% | -1.97 Increased by +33.50% |
| Aug 11, 23 | -1.96 Increased by +59.17% | -1.54 Decreased by -27.27% |
| May 12, 23 | -2.92 Increased by +43.85% | -2.55 Decreased by -14.51% |
| Mar 31, 23 | -2.92 Increased by +47.86% | -2.97 Increased by +1.68% |
| Nov 10, 22 | -3.60 Increased by +18.18% | -4.40 Increased by +18.18% |
| Aug 12, 22 | -4.80 Increased by +40.00% | -4.13 Decreased by -16.22% |
| May 6, 22 | -5.20 Increased by +40.91% | -3.70 Decreased by -40.54% |
| Mar 30, 22 | -5.60 Increased by +6.67% | -4.80 Decreased by -16.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -3.59 M Increased by +52.16% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -4.34 M Increased by +59.12% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -6.23 M Increased by +46.39% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -6.32 M Increased by +47.73% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -7.51 M Increased by +24.05% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -10.62 M Increased by +70.55% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -11.62 M Decreased by -33.66% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -12.09 M Decreased by -97.32% | Decreased by N/A% Decreased by N/A% |